Pharmacoeconomics of spastic cerebral palsy

Cerebral palsy (CP) is one of the most widespread and socially significant neurological diseases that affect both various aspects of physical and psychoverbal development of children since birth and stages of their personal development and adaptation in society. Over the last years there has been an increase in the number of children with disabilities in Russia, and it should be noted that CP ranks first among neurological disabilities in children. Given the lifetime course of this disease, CP acquires a huge medical and socioeconomic relevance. In particular, it is necessary to use the most efficient medical technologies (from the point of view of both efficacy, safety and costs). Pharmacoeconomic analysis is the most suitable tool for solving these tasks. However, when performing pharmacoeconomic analysis in the field of cerebral palsy, as well as in any other disease area, it is obligatory to take into account certain peculiarities at the planning and implementation stages. The authors of the article have identified specific features of pharmacoeconomic analysis methods based on assessment of health technologies related to cerebral palsy.

спастичность, детский церебральный паралич, фармакоэкономический анализ, моделирование, анализ затрат, анализ эффективности, критерии эффективности, анализ «влияния на бюджет», оценка технологий здравоохранения, spasticity, cerebral palsy, pharmacoeconomic analysis, modeling, cost analysis, efficiency analysis, efficiency criteria, budget impact analysis, health technologies assessment

1. Baranov AA, Namazova-Baranova LS, Kurenkov AL, еt al. A comprehensive assessment of motor functions in patients with cerebral palsy: a teaching aid. Moscow: Pediatrician, 2014; 84 p. (in Russian)

2. Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 14 (1): 45–66.

3. Kulikov AYu, Litvinenko MM. Methodological foundations of modeling in conducting pharmacoeconomic studies: different levels of complexity and different values of the obtained results. Pharmacoeconomics: theory and practice 2014; 2 (2): 9–22 (in Russian).

4. Zmanovskaya VA, Levitina EV, Popkov DA, Butorina MN, Pavlova OL. Prolonged use of the drug botulinum toxin type a, Dysport® in the complex rehabilitation of children with spastic forms of cerebral palsy. J Neurol Psychiatry. SS Korsakov 2014; 7: 33–6 (in Russian).

5. Khabriev RU, Kulikov AYu, Arinina EE. Methodological basis of pharmacoeconomic analysis. Moscow: Medicine, 2011; 128 p. (in Russian)

6. Kulikov AYu, Ugrekhelidze DT. Pharmacoeconomic study of botulinum toxin type A in treatment of post-stroke spasticity in the upper limb. Pharmacoeconomics: theory and practice 2014; 2 (3) 38–46 (in Russian).

7. Kulikov AYu, Ugrekhelidze DT. Pharmacoeconomic analysis of different types of treatment for spastic forms of cerebral palsy. Pharmacoeconomics: theory and practice 2015; 2 (3) (in press) (in Russian).

8. Kanovský P, Bares M, Severa S, Richardson A. Long-term efficacy and tolerability of 4-monthly versus yearly botulinum toxin type A treatment for lower-limb spasticity in children with cerebral palsy. Dev Med Child Neurol 2009; 51: 6: 436–45.

9. Molenaers G, Desloovere K, Fabry G, De Cock P. The effects of quantitative gait assessment and botulinum toxin a on musculoskeletal surgery in children with cerebral palsy. J Bone Joint Surg Am. 2006; 88 (1):161–70.

10. The RF Government decree of 28 November 2014 № 1273 "On the programme of state guarantees of free rendering to citizens of medical care for 2015 and on planning period 2016 and 2017" (in Russian).